The traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.
John Strapp
Advertisement
Articles by John Strapp
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Tylenol Maker Sued While Kennedy Says No ‘Sufficient’ Evidence for Autism Link
2
Novo Nordisk’s Unsolicited Proposal to Acquire Metsera
3
Pharmaceutical Executive Daily: Thermo Fisher's $8.8 Billion Acquisition of Clario Holdings
4
Dropping US Vaccine Rates Cause Delay in CSL’s Plans to Spin Off Vaccine Division
5
